Venus Remedies

Venus Remedies EBITDA per Share

The EBITDA per Share of Venus Remedies (VENUSREM.NS) as of Nov 10, 2026 is 91.01 INR. In the previous year, EBITDA per Share was 47.53 INR — a change of 91.47% (higher).

EBITDA per Share

91.01INR

YoY

91.47%

Last updated:

EBITDA per Share of Venus Remedies is 2026 91.01 INR. EBITDA per Share of Venus Remedies was 2025 47.53 INR. It decreases by 91.47% higher compared to the previous year.

The Venus Remedies EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
21.69 INR
Jan 1, 2020
34.98 INR
Jan 1, 2021
44.20 INR
Jan 1, 2022
52.47 INR
Jan 1, 2023
52.63 INR
Jan 1, 2024
53.24 INR
Jan 1, 2025
47.53 INR
Jan 1, 2026
91.01 INR
The Venus Remedies EBITDA per Share history
YEAREBITDA per ShareYoY
91.01INR+91.47%
47.53INR-10.72%
53.24INR+1.16%
52.63INR+0.30%
52.47INR+18.71%
44.20INR+26.36%
34.98INR+61.24%
21.69INR-33.24%
32.50INR-16.07%
38.72INR+14.53%
33.80INR-7.11%
36.39INR-58.89%
88.52INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Venus Remedies Stock analysis

What does Venus Remedies do? Venus Remedies Ltd. manufactures and trades pharmaceutical products, focusing on injectables, tablets, and topical preparations for therapeutic segments including anti-infective, oncology, skin and wound care, and pain management. The company's brands such as Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, Ventaful, and Nervolize cater to critical care and super specialty markets. Its product portfolio addresses antimicrobial resistance (AMR), oncology, neurology, anticoagulants, and herbal solutions, serving medicine, surgery, neuro, and orthopedics. The firm operates in the Pharmaceutical Formulation segment with three manufacturing facilities. The company sells its pharmaceutical products to healthcare providers and institutions globally, targeting critical care and super specialty segments. Brands like Potentox and Vancoplus Combi are positioned for antimicrobial resistance (AMR) solutions, while Neurotol and Trois serve neurology and orthopedics. Supime and Zydotum focus on pain management and skin care, and Septiloc and Mucomelt address anticoagulants and wound care. Venus Remedies' formulations include injectables, tablets, and topical preparations for diverse therapeutic needs. Venus Remedies Ltd. generates revenue through the sale of its branded pharmaceutical products, including injectables, tablets, and topical preparations. The company's product lines target specific therapy areas such as AMR, oncology, skin and wound care, and pain management, with brands like Ventaful and Nervolize supporting neurology and anticoagulant markets. The firm's global reach in injectable manufacturing and focus on super specialty segments drive its market positioning within the Pharmaceutical Formulation segment. Venus Remedies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Venus Remedies stock

EBITDA per Share of Venus Remedies is 91.01 INR in 2026.

EBITDA per Share of Venus Remedies changed from 47.53 INR to 91.01 INR, representing a 91.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Venus Remedies since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Venus Remedies

All Key Metrics — Venus Remedies